Novo Nordisk's earnings fell by 20% following warnings about price pressures in 2026

Shares of Novo Nordisk, known for the medications Ozempic and Wegovy, have dropped by up to 20% after the company announced it would face unprecedented pricing pressures in 2026, which will lead to a sales decline of up to 13% this year.

This negative estimate is influenced by initiatives to reduce prices in the U.S. and increasing competition in the weight loss treatment market. CEO Mike Doustdar mentioned that although the financial impact will be painful, it is an investment in the future. The drop in shares has wiped out over 40 billion euros from the company's market capitalization. Additionally, Novo Nordisk is facing increasing competition and issues related to 'copycat' drugs. However, strong sales of the new oral treatment Wegovy offer a glimmer of hope, with weekly prescriptions exceeding expectations.